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DNA repair is critical in maintaining 
genomic integrity and survival of all cells, 
and is especially important in the lungs. 
Lung tissue is exposed to a wide array of 
exogenous chemicals and insults on a con-
stant basis. Many of these agents are capa-
ble of inducing DNA damage and repair-
ing this damage is critical to maintain 
proper lung function. DNA damage result-
ing from these agents ranges from double 
strand breaks, single strand breaks, base 
damages, bulky adducts, intra- and inter-
strand cross links as well as breakdown of 
replication fork lesions. Upon recognizing 
DNA damage, cells initiate a myriad of 
signaling pathways collectively referred 
to as DNA damage response (DDR). The 
activation of DDR leads to DNA repair, 
suppression of global translation, cell cycle 
arrest and ultimately, either cell survival or 
cell death [1]. Major DNA repair pathways 
include homologous recombination (HR), 
nonhomologous end joining (NHEJ), base 
excision repair (BER), nucleotide excision 
repair (NER), direct enzymatic repair 
(DR) and mismatch repair (MMR), with 
certain pathways more active than others in 
various types of DNA damage. Mutations 
in DNA repair genes contribute to cancer 
development but can be exploited in favor 
of cancer therapy.
Exposure to tobacco smoke, containing 
an average of 1010 particles/ml and over 
60 carcinogens, is a major risk factor for 
both NSCLC and small-cell lung cancer 
(SCLC). These carcinogens lead to for-
mation of DNA adducts. In the presence 
of effective DNA repair processes, these 
adducts are rapidly eliminated by NER 
and BER pathways. If unrepaired damage 
is still present during DNA replication, 
usually the replication is arrested, eventu-
ally resulting in cell death. Alternatively, 
the DNA adducts are bypassed incorrectly 
resulting in genetic mutations in oncogenes 
or tumor suppressor genes leading to devel-
opment of malignant clone. Since smok-
ers are constantly exposed to carcinogens, 
their susceptibility to development of these 
mutations increases, culminating into 
development of cancer. Although, approxi-
mately 80–90% of lung cancer patients are 
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smokers, only 10% of the heavy smokers actually 
develop lung cancer, indicating a potential for 
genetic predisposition to this disease, including 
defects in DNA repair mechanisms. For exam-
ple, a molecular epidemiologic case control study 
investigating the association between develop-
ment of lung cancer and the activity of DNA 
repair enzyme OGG, which repairs the oxida-
tive DNA lesion induced by smoking, found that 
individuals in the lowest tertile of OGG activ-
ity had an increased risk of NSCLC compared 
with individuals in the highest tertile (odds 
ratio [OR]: 4.8; 95% CI: 1.5–15.9) [2]. Another 
association study with 1655 single nucleotide 
polymorphisms (SNPs) in 211 DNA repair 
genes evaluating 6911 individuals pooled from 
four genome-wide case–control studies in the 
International Lung Cancer Consortium iden-
tified three DNA repair genes associated with 
lung cancer (UBE2N, structural maintenance of 
chromosomes 1L2 and POLB). Two additional 
genes (RAD52 and POLN ) were borderline 
significant [3]. In addition, suboptimal DNA 
repair capacity (DRC) as measured by the host 
cell reactivation assay was found to be associated 
with a higher risk of lung cancer in never smok-
ers as well (OR: 1.92; 95% CI: 1.3–2.9). There 
was a 3.38-fold higher risk for individuals with 
DRC below the first quartile compared with 
individuals with DRC above the third quar-
tile [4]. Interestingly, it has also been found that 
patients with multiple primary NSCLC tumors 
have higher burden of DNA damage compared 
with patients with single primary tumor after 
controlling for age, sex, smoking history and 
treatment [5]. Collectively these data suggest that 
defective DNA repair might be associated with 
increased risk of lung cancer.
DNA repair plays a major role in sensitivity 
of lung cancer to platinum therapy. Platinum-
based chemotherapy agents, including cisplatin 
and carboplatin, represent the backbone for 
chemotherapy in lung cancer. Platinum exerts 
its antineoplastic effect by inducing formation 
of DNA lesions (intrastrand crosslinks, inter-
strand crosslinks and DNA–protein crosslinks). 
This DNA damage results in inhibition of DNA 
replication and activation of apoptotic pathways 
ultimately leading to cell death [6]. The bulky 
DNA adducts formed by cisplatin are predomi-
nantly repaired by NER pathway using either 
global genomic NER (GG-NER) or transcrip-
tion coupled NER (TC-NER), and to a lesser 
extent by HR pathway [7]. The main limitation 
for clinical efficacy of platinum agents is devel-
opment of intrinsic or acquired resistance to 
these therapies. Multiple mechanisms have been 
implicated including decreased accumulation of 
cisplatin into the cells and increased metabo-
lism, but enhanced repair of platinum-induced 
DNA damage appears to be the most important 
mechanism conferring platinum resistance. The 
search for a DNA repair biomarker for predict-
ing sensitivity to platinum has been ongoing. 
XPA and ERCC1 play a pivotal role in NER 
pathway. Several studies have shown correlation 
of overexpression of ERCC1 or XPA proteins 
with cisplatin resistance [8,9]. ERCC1 expression 
is perhaps the most extensively analyzed in clini-
cal trials and was evaluated as a biomarker for 
overall survival following cisplatin-based adju-
vant chemotherapy in patients with resected lung 
cancer. The initial study demonstrated that only 
patients with ERCC1-negative tumors benefited 
from adjuvant cisplatin-based therapy compared 
with ERCC1-positive tumors. ERCC1 expres-
sion was evaluated by immunohistochemistry 
using the 8F1 antibody [10]. Unfortunately, 
repeat evaluation using the same antibody failed 
to confirm these results [11]. The rationale for 
ERCC1 as a possible predictive biomarker for 
cisplatin response remains scientifically sound 
as ERCC1 forms a heterodimer with XPF and 
together they perform a critical incision step in 
NER response to platinum. ERCC1–XPF com-
plex is also involved in HR and ICL repair [12]. 
In addition, low ERCC1 expression has been 
connected to testicular cancer sensitivity to 
platinum as well. However, ERCC1 as a predic-
tive biomarker has failed in the clinical setting 
likely due to technical limitations as it does not 
seem that the antibodies used for immunohis-
tochemistry are appropriate since none of the 
available antibodies accurately differentiate the 
functional ERCC1 isoform [13]. Other possible 
biomarkers for platinum response include a 
number of NER or HR genes including BRCA1, 
XPA, RAD51 and EME1 [14,15]. It is likely that 
a single protein will not be predictive as repair 
of platinum-induced damage is orchestrated by 
multiple DNA repair components. The function 
of these components is not uniformly reflected 
via gene expression and both the DNA repair 
protein as well as the assay used to measure its 
function is critical.
The same defective DNA repair pathways that 
contribute to carcinogenesis and confer sensi-
tivity or resistance to chemotherapeutic agents 
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can be exploited as potential therapeutic targets. 
Although germline mutations in BRCA gene are 
uncommon in NSCLC, BRCAness defined as 
somatic molecular defects in the cellular DNA 
repair machinery, resulting in a phenotype simi-
lar to that caused by BRCA germline mutations 
is commonly observed in NSCLC. A recent 
study evaluating data from The Cancer Genome 
Atlas (TCGA) revealed that 53% of lung adeno-
carcinoma (LUAD) and 51% of squamous cell 
lung cancer (SQCC) had somatic alterations in 
at least one HR or FA (Fanconi Anemia) gene. 
The most common homozygous deletions noted 
were in RAD51 (3%) in LUAD and XRCC1 
(1%) in SQCC. LUAD had frequent somatic 
gene mutations in BRCA2 (5%), BRCA1 (3%), 
RAD54B (3%) and BRIP1 (3%), while SQCC 
had somatic mutations in BRCA1 (6%), BRCA2 
(6%), FANCA (3%) and PALB2 (3%) [16]. The 
tumor suppressor proteins BRCA1 and BRCA2 
regulate the initial steps of HR by orchestrating 
the assembly of the DNA recombinase-RAD51 
onto broken DNA ends at the site of double 
strand breaks (DSBs) and stalled replication 
forks. Defects in BRCA1 or BRCA2 cause a pro-
found defect in HR that predicts sensitivity to 
PARP inhibition through synthetic lethality [17]. 
A Phase III ECLIPSE study (NCT01082549) 
evaluating the combination of a weak PARP1 
inhibitor with gemcitabine–carboplatin as first-
line treatment in metastatic NSCLC has been 
recently completed. A similar Phase III trial was 
negative in triple-negative breast cancer [18]. As 
PARP is not involved in the repair of platinum-
induced DNA damage, it is unlikely the com-
bination will be more synergistic. Nevertheless, 
PARP inhibitors can potentially have a role in 
the treatment of a subset of NSCLC tumors, 
possibly the BRCA-like ones.
DNA repair pathways are being explored as 
potential therapeutic targets in SCLC as well. 
Being an extremely chemosensitive tumor, 
platinum-based chemotherapy remains the 
backbone of the treatment in both limited- and 
extensive-stage SCLC. However, a subset of 
tumors demonstrates inherent or acquired resist-
ance to platinum. Therefore, it is of paramount 
importance to explore the ways of circumvent-
ing this resistance. Proteomic analysis of SCLC 
cell lines has identified overexpression of several 
DNA repair proteins, especially PARP1 [19]. In a 
Phase I study of BMN 673 that included 23 pre-
viously treated SCLC patients, two patients had 
a partial response, while three had prolonged 
stable disease suggesting single-agent activity in 
some patients with SCLC [20]. However, the true 
clinical significance of PARP inhibition remains 
to be proven with larger clinical trials.
In summary, DNA repair might be involved 
in an individual’s susceptibility to lung cancer. 
Lung cancer including small cell, squamous cell 
and adenocarcinomas are characterized by their 
high mutational burden resulting from decades 
of smoking-induced DNA damage. DNA repair 
plays an important role in determining platinum 
response in lung cancer. In addition, DNA repair 
defects have been recently described in lung can-
cer tumor samples suggesting discovery of new 
agents that exploit these defects should be pur-
sued. Currently, there are no reliable biomarkers 
available to predict sensitivity to platinum agents 
but DNA repair pathways continue to represent 
the most likely players in platinum resistance.
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